Form 8-K - Current report:
SEC Accession No. 0001213900-25-072312
Filing Date
2025-08-06
Accepted
2025-08-06 07:34:51
Documents
13
Period of Report
2025-08-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0251994-8k_helix2.htm   iXBRL 8-K 30454
2 PRESS RELEASE, DATED AUGUST 6, 2025 ea025199401ex99-1_helix2.htm EX-99.1 9895
  Complete submission text file 0001213900-25-072312.txt   214198

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hlxb-20250806.xsd EX-101.SCH 3041
4 XBRL LABEL FILE hlxb-20250806_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE hlxb-20250806_pre.xml EX-101.PRE 22376
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0251994-8k_helix2_htm.xml XML 3815
Mailing Address C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 857 702 0377
Helix Acquisition Corp. II (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41955 | Film No.: 251187471
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)